Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SEIZALAM vs TRILAFON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.
Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.
Status epilepticus,Acute repetitive seizures,Seizure clusters
Schizophrenia,Schizoaffective disorder,Severe nausea and vomiting (in adults),Bipolar disorder (off-label)
0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day
8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.
Terminal elimination half-life is 15–20 hours in adults; prolonged in elderly and hepatic impairment (up to 40 hours).
Terminal elimination half-life is approximately 10–20 hours (mean ~12 hours); supports twice-daily dosing.
Hepatic via CYP3A4 and glucuronidation; active metabolite N-desmethylclobazam.
Extensively metabolized in the liver via glucuronidation, sulfoxidation, side-chain oxidation, and N-dealkylation. CYP2D6 is a major enzyme involved in metabolism; polymorphisms can lead to poor metabolizer status.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are excreted renally (approx. 70%) and fecal/biliary (approx. 30%).
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for the majority of elimination.
Approximately 98% bound to albumin.
90–95% bound, primarily to albumin and alpha-1-acid glycoprotein.
1.0–1.5 L/kg; reflects extensive tissue distribution.
Approximately 10–15 L/kg; large Vd indicates extensive tissue distribution.
Oral: 70–90%; Intramuscular: 80–95% (relative to IV).
Oral: 40–50% (due to first-pass metabolism); IM: 100% (assumed complete absorption).
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: reduce dose by 50%; hemodialysis: 0.25 mg daily
No dosage adjustment required for GFR 10-50 m L/min; use 50% of normal dose if GFR <10 m L/min.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
0.01 mg/kg/dose (up to 0.5 mg) twice daily, titrate weekly to max 0.1 mg/kg/day (not to exceed adult max)
Not recommended for children under 12 years; for ages 12 and older, 6-12 mg orally 2-3 times daily; maximum 24 mg/day.
0.25 mg once daily initially; titrate slowly to 0.5 mg twice daily; max 2 mg/day
Initiate at 4-8 mg orally daily; increase slowly; monitor for QT prolongation, hypotension, and tardive dyskinesia.
Risk of respiratory depression, hypotension, and cardiac arrest; coadministration with CNS depressants increases risk.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Perphenazine is not approved for the treatment of dementia-related psychosis.
Respiratory depression, hypotension, sedation, tolerance, withdrawal seizures, abuse potential, paradoxical reactions.
Extrapyramidal symptoms (including tardive dyskinesia) may occur,Neuroleptic malignant syndrome (NMS) - potentially fatal,QT prolongation and risk of arrhythmias,Orthostatic hypotension,Seizures (lower seizure threshold),Leukopenia, neutropenia, and agranulocytosis,Hematologic toxicity,Hyperprolactinemia,Cognitive and motor impairment,Antiemetic effect may mask signs of toxicity or overdose,Use in elderly with dementia not approved
Hypersensitivity to benzodiazepines, severe respiratory insufficiency, myasthenia gravis, narrow-angle glaucoma.
Hypersensitivity to perphenazine or any component of the formulation,Comatose states,CNS depression due to alcohol, barbiturates, or other drugs,Subcortical brain damage,Blood dyscrasias,Bone marrow suppression,Severe hypotension,Known QT prolongation or concurrent use with QT-prolonging drugs
Grapefruit and grapefruit juice may increase midazolam levels; avoid concurrent use. High-fat meals may reduce absorption of oral formulation; administer on empty stomach if possible.
Avoid grapefruit and grapefruit juice as they may increase perphenazine levels. Limit caffeine intake as it may worsen side effects like restlessness. Taking with food may reduce GI upset but avoid high-fat meals which can affect absorption.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restriction, preterm birth, neurodevelopmental deficits. Chronic use: Neonatal withdrawal syndrome, floppy infant syndrome.
First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal in neonates after late third trimester exposure. Overall, use only if benefit outweighs risk; avoid during organogenesis.
M/P ratio 0.8; excreted into breast milk; levels low (0.1-0.5 mg/L). Monitor infant for sedation, poor feeding, weight loss. Caution recommended; alternative therapy if infant shows adverse effects.
Trilafon (perphenazine) is excreted into human milk in small amounts; M/P ratio unknown. Monitor infant for drowsiness, irritability, or movement disorders. Use with caution during breastfeeding.
Increased clearance and volume of distribution in pregnancy; dose increase of 30-50% often required to maintain therapeutic levels. Monitor trough concentrations and adjust as needed, especially in third trimester.
No established dose adjustment per se; start at lowest effective dose. Increased plasma volume and metabolism during pregnancy may require dose increases to maintain efficacy; individualize based on response and tolerability.
SEIZALAM (midazolam) is a short-acting benzodiazepine used for acute seizure control. Administer IV/IM; intranasal formulation available. Onset within 2-5 minutes. Monitor respiratory depression, especially with concurrent opioids. Flumazenil is reversal agent. Avoid in narrow-angle glaucoma. Dose adjust in elderly and hepatic impairment.
TRILAFON (perphenazine) is a typical antipsychotic with potent antiemetic properties. Monitor for extrapyramidal symptoms (EPS), especially akathisia and dystonia. Avoid use in patients with CNS depression or bone marrow suppression. May lower seizure threshold; use cautiously in epilepsy. QT prolongation risk requires ECG monitoring. Taper dose when discontinuing to avoid withdrawal dyskinesias.
Take exactly as prescribed; do not stop abruptly to avoid withdrawal seizures.,May cause drowsiness, dizziness; avoid driving or operating machinery.,Avoid alcohol and other CNS depressants.,Report any difficulty breathing, severe sedation, or rash immediately.,Store at room temperature away from light and moisture.
Avoid alcohol and other CNS depressants.,Report any involuntary muscle movements, stiffness, or restlessness immediately.,May cause drowsiness; avoid driving until you know how the medication affects you.,Rise slowly from sitting or lying to prevent dizziness.,Use sun protection as this drug may increase sensitivity to sunlight.,Do not stop taking abruptly without consulting your doctor.,Inform all healthcare providers that you are taking this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SEIZALAM vs TRILAFON, answered by our medical review team.
SEIZALAM is a Benzodiazepine Anticonvulsant that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.. TRILAFON is a Phenothiazine Antipsychotic that works by Perphenazine is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the brain, exerting antipsychotic effects. It also has alpha-adrenergic blocking, anticholinergic, and antihistaminic properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SEIZALAM and TRILAFON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SEIZALAM is: 0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day. The standard adult dose of TRILAFON is: 8-16 mg orally twice daily; maximum 64 mg/day. Also 5-10 mg IM every 4-6 hours, maximum 30 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SEIZALAM and TRILAFON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SEIZALAM is classified as Category C. First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restrict. TRILAFON is classified as Category C. First trimester: Periconceptional use associated with neural tube defects? Limited data; avoid if possible. Second and third trimesters: Risk of extrapyramidal symptoms and/or with. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.